Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

FcγRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP)

Leukemia volume 18, pages 2038–2040 (2004)Cite this article

TO THE EDITOR

The therapeutic effect of the chimeric anti-CD20 IgG1 rituximab (Mabthera, Rituxan) which is widely used in the treatment of B-cell non-Hodgkin's lymphomas involves the triggering of Fcγ receptor-positive effector cells and/or the activation of complement.1 The clinical value in follicular lymphoma of polymorphisms of the activating members of the FcγR family, FcγRIIIA (CD16) and FcγRIIA (CD32) expressed on NK and macrophages, suggests that antibody-dependent cell-mediated cytotoxicity (ADCC) may be the major effector mechanism.2, 3 We have shown that, although downregulated in reactive germinal center B cells, FcγRIIB is expressed by one-fifth of diffuse large B-cell lymphomas (DLBCL).4 Expression of FcγRIIB on tumor cells could interfere with rituximab action. It may bind the Fc portion of the therapeutic antibody and thus compete for binding with the activating FcγR or with complement which are required for ADCC and CDC, respectively. In addition, FcγRIIB being an inhibitory receptor,5 its expression may have a direct negative effect on tumor cells upon ligation with immune complexes. To address the questions of the prognostic impact of FcγRIIB expression and its potential influence on rituximab efficacy, we have investigated retrospectively 234 patients included in the LNH-98.5 from the GELA (Groupe d'Etude des Lymphomes de l'Adulte) which has shown that the combination of rituximab and CHOP (R-CHOP) was more effective than CHOP alone.6

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101: 949–954.

    Article  CAS  Google Scholar 

  2. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 754–758.

    Article  CAS  Google Scholar 

  3. Weng WK, Levy R . Two immunoglobulin G Fc receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940–3947.

    Article  CAS  Google Scholar 

  4. Camilleri-Broet S, Cassard L, Broet P, Delmer A, Le Touneau A, Diebold J et al. FcγRIIB is differentially expressed during B cell maturation and in B-cell lymphomas. Br J Haematol 2004; 124: 55–62.

    Article  CAS  Google Scholar 

  5. Hulett MD, Hogarth PM . Molecular basis of Fc receptor function. Adv Immunol 1994; 57: 1–127.

    Article  CAS  Google Scholar 

  6. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242.

    Article  CAS  Google Scholar 

  7. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279–4284.

    Article  CAS  Google Scholar 

  8. Fridman WH, Teillaud JL, Bouchard C, Teillaud C, Astier A, Tartour E et al. Soluble Fcγ receptors. J Leuk Biol 1993; 54: 504–512.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We wish to thank WH Fridman, J Diebold and T Molina for their stimulating discussion, C Régnier for reviewing the manuscript and B Marmey for her expert technical support. They also wish to acknowledge the contributions of the following persons involved in the 98.5 trial: External advisory committee – E Montserrat, M Björkholm, M Buyse, F Cavalli, and M Pfreundschuh; Pathological review committee – J Brière, P Gaulard, J Bosq, JF Emile, B Fabiani, and T Petrella; Pathological technicians: C Coppeaux, K Sardin; Statistics – E Lepage and N Nio; Pharmacist – I Madelaine; GELA clinical research – R Chvetzoff; Investigators – B Coiffier, G Salles, R Herbrecht, H Tilly, P Solal-Celigny, R Bouabdallah, P Lederlin, C Sebban, JN Munck, C Fermé, P Morel, F Reyes, C Haioun, M Blanc, B Christian, B Quesnel, A van Hoof, C Gisselbrecht, M Attal, D Bordessoule, V Delwail, A Bosly, M Macro, G Marit, J Gabarre, S Castaigne, E Jourdan, E Lepeu, B Audhuy, A Thyss, N Albin, E Baumelou, A Delmer, S Lefort, H Orfeuvre, I Plantier, G Tertian, B Varet, F Boué, O Casasnovas, D Caillot, E Van Den Neste, D Decaudin P Brice, H Dombret, JP Fermand, JM Zini, G Fillet, M Flesch, Y Kerneis, C Martin, PY Péaud, P Rodon, C Rose, P Travade, B Velay, F Bauduer, K Bouabdallah, JC Eisenmann, C Kulekci, S Lampertz, G Nedellec, AM Peny, V Pulik, B Salles, X Vallantin, P Agranat, JP Cassuto, J Collignon, B de Prijck, A Delannoy, A Devidas, JF Dor, F Dreyfus, C Dubois, G Dupont, M Fabbro, C Fruchart, JP Gaillard, B Grosbois, M Janvier, N Ketterer, C Leroy, M Maerevoet, F Marechal, P Mineur, P Pierre, G Sebahoun, C Soussain, C Traulle. Financial support from Association pour la recherche contre le cancer (ARC-ARECA) and Institut National de la Santé et de la Recherche Médicale (INSERM).

Author information

Authors and Affiliations

  1. Anatomie Pathologique, Hotel-Dieu, AP-HP, Universite Paris V, France

    S Camilleri-Broët

  2. INSERM U255, Centre de Recherches Biomedicales des cordeliers, Universite Paris VI, France

    S Camilleri-Broët, L Cassard & C Sautès-Fridman

  3. Service d'Hematologie, Hopital Saint Louis, AP-HP, France

    N Mounier

  4. Service d'Hematologie, Hotel Dieu, AP-HP, France

    A Delmer

  5. Anatomie Pathologique, Hopital Saint Louis, AP-HP, France

    J Brière

  6. Service d'Hematologie, CHU Dijon, France

    O Casasnovas

  7. Anatomie Pathologique, Hopital Henri Mondor, AP-HP, France

    P Gaulard

  8. Service de Médecine A- Hematologie clinique, Hopital N-D de Bon, Secours, METZ, France

    B Christian

  9. Service d'Hematologie, Centre hospitalier Lyon Sud, for the Groupe d'Etude des Lymphomes de l'Adulte (GELA), France

    B Coiffier

Authors
  1. S Camilleri-Broët
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Mounier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Delmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Brière
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O Casasnovas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L Cassard
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P Gaulard
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B Christian
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. B Coiffier
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C Sautès-Fridman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Camilleri-Broët.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Camilleri-Broët, S., Mounier, N., Delmer, A. et al. FcγRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP). Leukemia 18, 2038–2040 (2004). https://doi.org/10.1038/sj.leu.2403536

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403536

This article is cited by

Search

Advanced search

Quick links